Primary malignant melanoma of the esophagus: Clinical features, signaling pathway, management, and survival.

Xuan Wang,Lu Si,Yan Kong,Zhihong Chi,Chuan Liang Cui,Xi Nan Sheng,Bin Lian,Li Li Mao,Jun Guo
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e20015
IF: 45.3
2017-01-01
Journal of Clinical Oncology
Abstract:e20015 Background: Primary malignant melanoma of the esophagus (PMME) is a rare disease that has a poor prognosis and develops multiple metastases in the early stage. Treatment protocols are not well-established. Methods: Clinical data of 28 cases of PMME were retrospectively analyzed including clinical features, signaling pathway, management and survival in Peking University Cancer Hospital between 2006 and 2013. Somatic mutations in genes in MAP kinase (c-Kit, BRAF, NRAS) were detected by DNA sequencing. PI3K-AKT-mTOR (pmTOR, pS6RP, p4E-BP1 and pAKT) were examined by immunohistochemistry (IHC) assays. Results: 1) Clinical features:The average age was 56.4 years, and 75.0% were male. Overall, most tumors were located in the lower thoracic esophagus (53.6%) and majority were in early stages (I to III-85.7% according to 7th UICC TNM) when diagnosed. 24/28 patients accepted subtotal esophagectomy with lymph node dissection. 16/24 patients underwent adjuvant chemotherapy consisted of four courses of dacarbaz...
What problem does this paper attempt to address?